|
|
|
|
|
|
by oldgradstudent
1109 days ago
|
|
|
> Hard to take much meaning away from that without understanding the risk posed by not vaccinating. What's the benefit from vaccinating otherwise healthy young men against Covid? Not people in risk groups, but healthy young men. It should be obvious that if your clinical trials cannot rule out major adverse events in 1 in N, you shouldn't vaccinate populations in which the benefit occurs in less than 1 in N. > If vaccines can prevent long COVID or "post viral syndrome, that's another potential cost benefit analysis. That's a big "If". |
|
|